Post by icemandios on Apr 13, 2022 17:50:00 GMT
COVID-19 public health emergency extended another 90 days
The COVID-19 public health emergency that was set to expire on April 16 has been extended by 90 days into mid-July by Health and Human Services Secretary Xavier Becerra, Reuters reported. The emergency has required private health insurers to cover to cover the cost of COVID tests and vaccines with no costs passed on to consumers. Republican have asked that the emergency end. In February, more than 70 House Republicans asked the Biden administration to do so citing COVID's progression to endemic status and a return to more normal living. At-home COVID test makers: Quidel (QDEL), Abbott (NYSE:ABT), Roche (OTCQX:RHHBY), OraSure (OSUR), Becton, Dickinson (BDX), Cue Health (HLTH), and Lucira Health (LHDX). COVID vaccine makers: Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), BioNTech (BNTX), Johnson & Johnson (NYSE:JNJ), AstraZeneca (AZN), and Novavax (NVAX). Earlier in April, Senate leaders agreed on $10B in additional funding for the nation's COVID response.
For further details see:
COVID-19 public health emergency extended another 90 days
Source: SeekingAlpha (Apr 13, 2022 13:37:01 EDT)
The COVID-19 public health emergency that was set to expire on April 16 has been extended by 90 days into mid-July by Health and Human Services Secretary Xavier Becerra, Reuters reported. The emergency has required private health insurers to cover to cover the cost of COVID tests and vaccines with no costs passed on to consumers. Republican have asked that the emergency end. In February, more than 70 House Republicans asked the Biden administration to do so citing COVID's progression to endemic status and a return to more normal living. At-home COVID test makers: Quidel (QDEL), Abbott (NYSE:ABT), Roche (OTCQX:RHHBY), OraSure (OSUR), Becton, Dickinson (BDX), Cue Health (HLTH), and Lucira Health (LHDX). COVID vaccine makers: Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), BioNTech (BNTX), Johnson & Johnson (NYSE:JNJ), AstraZeneca (AZN), and Novavax (NVAX). Earlier in April, Senate leaders agreed on $10B in additional funding for the nation's COVID response.
For further details see:
COVID-19 public health emergency extended another 90 days
Source: SeekingAlpha (Apr 13, 2022 13:37:01 EDT)